Atossa Therapeutics (Germany) Today
| YAG2 Stock | EUR 1.15 0.04 3.60% |
Performance0 of 100
| Odds Of DistressOver 68
|
Atossa Therapeutics is trading at 1.15 as of the 26th of November 2024. This is a 3.60 percent increase since the beginning of the trading day. The stock's lowest day price was 1.15. Atossa Therapeutics has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Atossa Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. The company has 126.62 M outstanding shares. More on Atossa Therapeutics
Moving against Atossa Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Atossa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Atossa Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Atossa Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Atossa Therapeutics (YAG2) is traded on Frankfurt Exchange in Germany and employs 6 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 88.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atossa Therapeutics's market, we take the total number of its shares issued and multiply it by Atossa Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Atossa Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 126.62 M outstanding shares.
Atossa Therapeutics has accumulated about 131.49 M in cash with (16.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Check Atossa Therapeutics Probability Of Bankruptcy
Ownership AllocationAtossa Therapeutics holds a total of 126.62 Million outstanding shares. Almost 79.31 percent of Atossa Therapeutics outstanding shares are held by general public with 0.04 (percent) owned by insiders and only 20.65 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Atossa Ownership Details
Atossa Therapeutics Risk Profiles
Although Atossa Therapeutics' alpha and beta are two of the key measurements used to evaluate Atossa Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.48 | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.18 | |||
| Risk Adjusted Performance | (0.01) |
Atossa Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Atossa Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
Atossa Therapeutics Corporate Management
Elected by the shareholders, the Atossa Therapeutics' board of directors comprises two types of representatives: Atossa Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atossa. The board's role is to monitor Atossa Therapeutics' management team and ensure that shareholders' interests are well served. Atossa Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atossa Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heather Rees | VP Accounting | Profile | |
| FCAP MD | CEO Chairman | Profile | |
| Delly PHR | VP HR | Profile | |
| RAC MSPH | Quality Regulatory | Profile | |
| Richard MD | Interim Officer | Profile | |
| CPA Esq | Gen CFO | Profile |
Other Information on Investing in Atossa Stock
Atossa Therapeutics financial ratios help investors to determine whether Atossa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atossa with respect to the benefits of owning Atossa Therapeutics security.